ENLIVEN THERAPEUTICS, INC. Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect
ENLIVEN THERAPEUTICS, INC. (ELVN) reported Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect of $36.61 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Cash Flow
us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect · last filed 2026-08-05
- ENLIVEN THERAPEUTICS, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2026-03-31 was $33.29M.
- ENLIVEN THERAPEUTICS, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2025-03-31 was -$22.47M, a 145.83% decline year-over-year.
- ENLIVEN THERAPEUTICS, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2024-03-31 was $49.02M, a 77.36% decline year-over-year.
- ENLIVEN THERAPEUTICS, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2023-03-31 was $216.57M.
- ENLIVEN THERAPEUTICS, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2025 was -$25.27M, a 205.42% decline from fiscal 2024.
- ENLIVEN THERAPEUTICS, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2024 was $23.98M, a 2.56% decline from fiscal 2023.
- ENLIVEN THERAPEUTICS, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2023 was $24.61M.
- ENLIVEN THERAPEUTICS, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2022 was -$34.49M.
| Period end | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 3 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 3 month as first filed | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 6 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 6 month as first filed | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 9 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 9 month as first filed | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 12 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $36.61M 10-Q · filed 2026-08-05 | |||||||
| 2026-03-31 | $33.29M 10-Q · filed 2026-05-07 | |||||||
| 2025-12-31 | -$25.27M 10-K · filed 2026-03-03 | |||||||
| 2025-09-30 | -$22.44M 10-Q · filed 2025-11-12 | |||||||
| 2025-06-30 | -$4.73M 10-Q · filed 2026-08-05 | |||||||
| 2025-03-31 | -$22.47M 10-Q · filed 2026-05-07 | |||||||
| 2024-12-31 | $23.98M 10-K · filed 2026-03-03 | |||||||
| 2024-09-30 | $480.00K 10-Q · filed 2025-11-12 | |||||||
| 2024-06-30 | -$3.27M 10-Q · filed 2025-08-13 | |||||||
| 2024-03-31 | $49.02M 10-Q · filed 2025-05-14 | |||||||
| 2023-12-31 | $24.61M 10-K · filed 2025-03-13 | |||||||
| 2023-09-30 | -$1.69M 10-Q · filed 2024-11-13 | |||||||
| 2023-06-30 | $50.18M 10-Q · filed 2024-08-13 | |||||||
| 2023-03-31 | $216.57M 10-Q · filed 2024-05-14 | |||||||
| 2022-12-31 | -$34.49M 10-K · filed 2024-03-14 | $39.71M 10-K · filed 2023-02-10 | ||||||
| 2022-09-30 | -$23.86M 10-Q · filed 2023-11-09 | $1.01M 10-Q · filed 2022-10-25 | ||||||
| 2022-06-30 | -$17.57M 10-Q · filed 2023-08-10 | -$17.88M 10-Q · filed 2022-08-03 | ||||||
| 2022-03-31 | -$10.15M 10-Q · filed 2023-05-11 | -$11.82M 10-Q · filed 2022-05-06 | ||||||
| 2021-12-31 | -$20.34M 8-K · filed 2023-06-23 | $698.00K 10-K · filed 2022-03-15 | ||||||
| 2021-09-30 | $27.68M 10-Q · filed 2022-10-25 | |||||||
| 2021-06-30 | $426.00K 10-Q · filed 2022-08-03 | |||||||
| 2021-03-31 | $5.74M 10-Q · filed 2022-05-06 | |||||||
| 2020-12-31 | $42.76M 10-K · filed 2022-03-15 | |||||||
| 2020-09-30 | $29.22M 10-Q · filed 2021-11-09 | |||||||
| 2020-06-30 | $49.72M 10-Q · filed 2021-08-06 | |||||||
| 2020-03-31 | $81.79M 10-Q · filed 2021-05-11 | |||||||
| 2019-12-31 | -$2.36M 10-K · filed 2021-03-05 | |||||||
| 2019-09-30 | $9.79M 10-Q · filed 2020-11-05 | |||||||
| 2019-06-30 | $37.94M 10-Q · filed 2020-08-14 | |||||||
| 2019-03-31 | $41.52M 10-Q · filed 2020-05-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Arcutis Biotherapeutics, Inc. (ARQT) | United States | $3.303B | 115.47 |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| Arcus Biosciences, Inc. (RCUS) | United States | $3.188B | -8.52 |
| Dyne Therapeutics, Inc. (DYN) | United States | $3.084B | -7.09 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| PRECIGEN, INC. (PGEN) | United States | $2.757B | -12.94 |
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 |